EUCTR2018-001209-95-IT进行中（未招募）1 期
An open-label Phase 2 study to assess the pharmacokinetics of Accordion Pill¿ Carbidopa-Levodopa compared to immediate release carbidopa-levodopa in patients with Parkinson¿s disease - IN 18001
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Men or women 30 years of age or older at screening
- •2.Diagnosis of Parkinson’s disease consistent with the UK Brain Bank Criteria
- •3.Stable doses of levodopa/carbidopa IR for at least 4 weeks prior to entry
- •4.Taking at least 4 doses of immediate release levodopa during waking hours
- •5.Taking a total levodopa daily dose of at least 400 mg prior to initial screening assessment
- •6.All anti-PD medications are permitted during the study but must be maintained on stable doses for at least 30 days prior to study entry (screening visit). COMT inhibitors will be held prior to PK studies on Day 1 and through Day 8.
- •7.Other than PD, the subject is in satisfactory health in the judgment of the investigator. No clinically significant medical, psychiatric or laboratory abnormality that could compromise safety or interfere with study procedures
- •8.Subjects must be approved for suitability by an Enrollment Authorization Committee.
- •9.Able and willing to give written (signed and dated) informed consent, and to comply with study requirements
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 4
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •1.Atypical or secondary parkinsonism
- •2.Clinically significant cardiac, pulmonary, hepatic or renal disease or other condition which contraindicates his/her participation in judgment of the investigator or the EAC
- •3.Severe dyskinesia as assessed by the PI or the Enrollment Authorization Committee
- •4.Significant cognitive impairment in the opinion of the Investigator.
- •5.Clinically significant psychiatric illness in the opinion of the Investigator, including psychotic attacks or major depression
- •6.Subjects with a history of suicide attempt (including an active attempt, interrupted attempt or aborted attempt) within the last 5 years.
- •7.Treatment within the past 28 days with a neuroleptic drug (antipsychotic) or any other drug with anti-dopaminergic properties (e.g. metoclopramide).
- •8.Currently experiencing or any known history of psychosis within the previous 2 years.
- •9.History of small bowel or gastric surgery (Including PEG-J placement for Duopa/Duodopa) or bowel obstruction, diagnosis of small bowel narrowing, diagnosis of Crohn’s disease, frequent nausea or emesis regardless of etiology, and symptomatic gastroparesis. (Previous appendectomy or hernioplasty will be not be exclusionary)
- •10.History of GI pathology of clinical significance as determined by the Investigator.
- •11.Regular use of opioids (Intermittent opioid use is not exclusionary)
- •12.Allergy to the study drug or any of its excipients or to Yellow Dye #5 (tartrazine)
- •13.History of drug or alcohol abuse within past 12 months
- •14.Use of an experimental drug within 30 days or five half-lives of screening
- •15.Unable to swallow large pills (e.g., large vitamin pills)
- •16.Active gastroesophageal reflux (GERD) and regular use of proton pump inhibitors (PPIs)
- •17.Women who are pregnant or nursing and women of childbearing potential (defined as from menarche and until becoming post-menopausal unless permanently sterile) who are not willing to use a highly effective method of contraception. Medically acceptable methods of contraception that may be used by the subject and/or partner include:
- •True abstinence when this is in line with the preferred and usual lifestyle of the subject,
- •combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation
- •ointravaginal
- •otransdermal (e.g., Ortho Evra),
- •Progestogen-only hormonal contraception associated with inhibition of ovulation
- •oinjectable (e.g., Dep-Provera),
- •oimplantable (e.g., Norplant),
- •intrauterine device (IUD),
- •surgical sterilization (>6 months),
- •Vasectomized partner (>6 months)
- •Postmenopausal female (no menstrual period for > 2years)
- •Hormonal contraceptive therapy must be at a stable dose for at least 90 days prior to first study drug administration. The current contraceptive therapy must be maintained through the end of the study (Safety Follow Up Visit or Early Termination Visit).
- •18.History of Narrow-angle Glaucoma.
- •19.History of Melanoma or suspicious skin lesion which could be a Melanoma.
- •20.Treatment with non-selective monoamine oxidase (MAO) inhibitors during the last 28 days prior to initial screening assessment or planning to take during study participation.
研究者
相似试验
进行中（未招募）
1 期
A study to assess the effects of a platelet inhibitor (RUC-4). This platelet inhibitor is given by a single subcutaneous injection.Targeted patients are patients with an acute myocardial infarction. The medication will be given on the cardiac catheterization lab. Subsequently a coronary angiography will be perormed and if needed the patient will be treated with primary coronary angioplastyPatients with STEMI, presenting with persistent chest pain (>30 min) and = 1 mm ST-segment elevation in two adjacent electrocardiograph leads, with > 6 mm cumulative ST-segment deviation, in whom the total duration of symptom to first intracoronary device deployment (excluding a wire) is anticipated to be within 6 hours. Patients are adult males and females 18 years of age or older.MedDRA version: 20.0Level: HLGTClassification code 10028593Term: Myocardial disordersSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10000891Term: Acute myocardial infarctionSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10028600Term: Myocardial ischaemiaSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 21.0Level: PTClassification code 10081099Term: Acute cardiac eventSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10062084Term: Platelet aggregationSystem Organ Class: 10022891 - InvestigationsMedDRA version: 20.1Level: PTClassification code 10050661Term: Platelet aggregation inhibitionSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2019-004282-41-NLCeleCor Therapeutics, Inc.30
已完成
2 期
A Phase-2 open label study to assess the pharmacodynamic and pharmacokinetic properties of a single subcutaneous injection of RUC-4 in patients with ST-elevation myocardial infarction presenting to cardiac catheterization lab with planned primary coronary angioplastyNL-OMON49794CeleCor Therapeutics, Inc.30
进行中（未招募）
不适用
TMC114-TiDP29-C228 – A safety study to evaluate the antiviral activity of darunavir (DRV) in combination with ritonavir (rtv) in HIV 1 infected children from 3 years to below 6 years of ageThe purpose of this Phase II trial is to evaluate the pharmacokinetics (blood levels), safety and antiviral activity to support dose recommendations by body weight of darunavir with low-dose ritonavir (DRV/rtv), in combination with other antiretroviral drugs (ARVs), in treatment-experienced HIV 1 infected children aged from 3 years to < 6 years and weighing between 10 kg and < 20 kg .MedDRA version: 16.1Level: LLTClassification code 10020192Term: HIV-1System Organ Class: 100000004862EUCTR2008-004630-25-Outside-EU/EEATibotec Pharmaceuticals24
进行中（未招募）
不适用
A safety study to evaluate the antiviral activity of darunavir in combination with ritonavir in HIV 1 infected adolescents between 12 and 18 years of age who have not received previous treatment with antiretroviral drugsHIV-1MedDRA version: 14.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2008-004631-37-Outside-EU/EEATibotec Pharmaceuticals12
进行中（未招募）
1 期
A Phase II, open-label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV/rtv once daily in treatment-naïve HIV 1 infected adolescents aged between 12 and < 18 years.This trial will be referred to as DIONE.Estudio en Fase II, abierto, para evaluar la farmacocinética, seguridad, tolerabilidad y actividad antiviral de DRV/rtv una vez al día en adolescentes infectados por VIH-1 de entre 12 y < 18 años de edad no tratados. Nos referiremos a este estudio como DIONE. - DIONEHIV-1VIH-1MedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infectionEUCTR2008-004631-37-ESTibotec Pharmaceuticals12